Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARGARET VON MEHREN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1144243858
CMS profile
233516
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,481.32

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,480.00 2
Food and Beverage $1.32 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Exelixis Inc. $1,980.00 1
PFIZER INC. $1,501.32 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARGARET VON MEHREN

NPI 1144243858 · CMS profile ID 233516

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $3,481.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exelixis Inc. $1,980.0005/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686543021 CMS
PFIZER INC. $1,500.0001/17/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673757429 CMS
PFIZER INC. $1.3201/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673262617 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,481.32 3
PY2022 $16,889.37 14
PY2024 $17,850.01 21
PY2025 $107.49 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $439.96 2
PY2025 Principal investigator $3,999,133.04 151
PY2024 Principal investigator $2,114,235.16 59
PY2023 Principal investigator $1,626,861.83 207
PY2022 Recipient $12,046.00 1
PY2022 Principal investigator $1,964,612.75 261
PY2021 Principal investigator $4,056,403.36 219
PY2020 Recipient $1,210.00 1
PY2020 Principal investigator $2,320,213.22 69
PY2019 Principal investigator $1,242,313.06 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

153 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,953.00 12/17/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976970
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,243.00 12/17/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976974
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,597.00 12/17/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976978
Principal investigator 1 Deciphera Pharmaceuticals Inc. $8,200.00 12/01/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976822
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,030.00 12/01/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976827
Principal investigator 1 Deciphera Pharmaceuticals Inc. $8,062.00 12/01/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976830
Principal investigator 1 Deciphera Pharmaceuticals Inc. $883.00 12/01/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976834
Principal investigator 1 Deciphera Pharmaceuticals Inc. $911.00 12/01/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976838
Principal investigator 1 Deciphera Pharmaceuticals Inc. $83.00 12/01/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976843
Principal investigator 1 Deciphera Pharmaceuticals Inc. $73,950.00 11/25/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235976306
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,732.00 11/19/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976186
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,953.00 11/19/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976190
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,454.00 11/19/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976193
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,732.00 11/19/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976196
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,953.00 11/19/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976199
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,454.00 11/19/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976203
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 11/17/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235976154
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 11/17/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235976158
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 11/17/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235976162
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,538.48 11/13/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235976103
Principal investigator 1 Novartis Pharmaceuticals Corporation $255,643.80 11/13/2025 Covered Recipient Teaching Hospital
Dana-Farber Cancer Institute
Phase II trial of Ribociclib in combination with Everolimus in advanced dedifferentiated liposarcoma DDL and leiomyosarcoma LMS No dispute reported 06/30/2026 1190296911
Recipient GlaxoSmithKline, LLC. $284.13 11/12/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY OF IDRX-42 (GSK60 No dispute reported 06/30/2026 1192144779
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,100.00 11/05/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975876
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,379.00 11/05/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975879
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,375.00 11/05/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975884
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,871.00 11/05/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975888
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,100.00 11/05/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975891
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,379.00 11/05/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975895
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,346.00 11/05/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975899
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,375.00 11/05/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975903
Principal investigator 1 Deciphera Pharmaceuticals Inc. $7,742.00 11/05/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975907
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,243.00 10/15/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975247
Principal investigator 1 Deciphera Pharmaceuticals Inc. $867.00 10/15/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975251
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,243.00 10/15/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975255
Principal investigator 1 Deciphera Pharmaceuticals Inc. $867.00 10/15/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975258
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,953.00 10/15/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975263
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,454.00 10/15/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975266
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,243.00 10/15/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975270
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,243.00 10/15/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975274
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,597.00 10/15/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975278
Principal investigator 1 Deciphera Pharmaceuticals Inc. $73,950.00 10/14/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235975196
Principal investigator 1 Deciphera Pharmaceuticals Inc. $162,690.00 10/14/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975200
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,175.84 10/09/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975158
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,100.00 10/08/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975095
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,015.00 10/08/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235975098
Principal investigator 1 Deciphera Pharmaceuticals Inc. $402.00 10/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235974825
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,480.00 10/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974830
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,671.00 10/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974833
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,137.00 10/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974837
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,623.00 10/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974842
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,243.00 10/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974846
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,953.00 10/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974850
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,243.00 10/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974853
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,423.00 10/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974857
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,445.00 10/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974861
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,845.00 10/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974865
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,423.00 10/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974871
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,631.88 09/17/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974467
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,100.00 09/12/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974232
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,379.00 09/12/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974236
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,375.00 09/12/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974242
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,871.00 09/12/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974250
Principal investigator 1 Deciphera Pharmaceuticals Inc. $8,062.00 09/12/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974254
Principal investigator 1 Deciphera Pharmaceuticals Inc. $883.00 09/12/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974258
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,364.00 09/12/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974262
Principal investigator 1 Deciphera Pharmaceuticals Inc. $10,750.00 09/12/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974267
Principal investigator 1 Deciphera Pharmaceuticals Inc. $7,742.00 09/12/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974272
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,639.00 09/12/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974276
Principal investigator 1 Deciphera Pharmaceuticals Inc. $883.00 09/12/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235974279
Principal investigator 1 Deciphera Pharmaceuticals Inc. $73,950.00 09/02/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235974146
Principal investigator 1 Deciphera Pharmaceuticals Inc. $147,900.00 08/26/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973946
Principal investigator 1 Deciphera Pharmaceuticals Inc. $133,110.00 08/25/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973930
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,243.00 08/14/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973677
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,243.00 08/14/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973680
Principal investigator 1 Deciphera Pharmaceuticals Inc. $530.00 08/14/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973684
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,243.00 08/14/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973688
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,243.00 08/14/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973691
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,243.00 08/14/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973695
Principal investigator 1 Deciphera Pharmaceuticals Inc. $220.00 08/14/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973699
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,845.00 08/14/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973703
Principal investigator 1 Deciphera Pharmaceuticals Inc. $8,200.00 08/11/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973592
Principal investigator 1 Deciphera Pharmaceuticals Inc. $8,394.00 08/11/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973596
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,375.00 08/11/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973599
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,871.00 08/11/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973603
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,300.00 08/06/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973556
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,631.88 08/06/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973579
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,100.00 08/04/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973500
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,015.00 08/04/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973503
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,346.00 08/04/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973507
Principal investigator 1 Deciphera Pharmaceuticals Inc. $147,900.00 07/30/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235973435
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,364.00 07/28/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973362
Principal investigator 1 Deciphera Pharmaceuticals Inc. $911.00 07/28/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973366
Principal investigator 1 Deciphera Pharmaceuticals Inc. $83.00 07/28/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973370
Principal investigator 1 Deciphera Pharmaceuticals Inc. $10,750.00 07/28/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973374
Principal investigator 1 Deciphera Pharmaceuticals Inc. $7,742.00 07/28/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973377
Principal investigator 1 Deciphera Pharmaceuticals Inc. $8,062.00 07/28/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973381
Principal investigator 1 Deciphera Pharmaceuticals Inc. $883.00 07/28/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235973385
Principal investigator 1 Deciphera Pharmaceuticals Inc. $73,950.00 07/22/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235973082
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,633.00 07/14/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235972978
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,445.00 07/14/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235972982
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,043.00 07/14/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235972986
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,450.56 07/09/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235972850
Principal investigator 1 Deciphera Pharmaceuticals Inc. $118,320.00 07/09/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235972865
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,000.00 07/07/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235972761
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 06/18/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235972546
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 06/18/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235972550
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 06/18/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235972553
Principal investigator 1 Deciphera Pharmaceuticals Inc. $72,450.00 06/12/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235972397
Recipient GlaxoSmithKline, LLC. $155.83 05/31/2025 Covered Recipient Physician A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATI No dispute reported 06/30/2026 1192144783
Principal investigator 1 Deciphera Pharmaceuticals Inc. $86,940.00 05/21/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235972038
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,450.56 05/20/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235972032
Principal investigator 1 Deciphera Pharmaceuticals Inc. $130,410.00 05/16/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971999
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,813.20 05/16/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235972003
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,000.00 05/07/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971813
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,364.00 05/02/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971776
Principal investigator 1 Deciphera Pharmaceuticals Inc. $72,450.00 04/30/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235971768
Principal investigator 1 Deciphera Pharmaceuticals Inc. $130,410.00 04/18/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971719
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,813.20 04/18/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971723
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,480.00 04/16/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971580
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,445.00 04/16/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971584
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,043.00 04/16/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971588
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,845.00 04/16/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971592
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,671.00 04/16/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971597
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,137.00 04/16/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971600
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,623.00 04/16/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971605
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,043.00 04/16/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971609
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,639.00 04/07/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971396
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,100.00 04/07/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971399
Principal investigator 1 Deciphera Pharmaceuticals Inc. $883.00 04/07/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971403
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,379.00 04/07/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971408
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,346.00 04/07/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971412
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,375.00 04/07/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971416
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,871.00 04/07/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971419
Principal investigator 1 Novartis Pharmaceuticals Corporation $219,545.84 04/01/2025 Covered Recipient Teaching Hospital
American Oncologic Hospial
An open label multi center imatinib rollover protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued imatinib treatment No dispute reported 06/30/2026 1190294501
Principal investigator 1 Deciphera Pharmaceuticals Inc. $130,410.00 03/21/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971138
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,813.20 03/21/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235971142
Principal investigator 1 Deciphera Pharmaceuticals Inc. $72,450.00 03/12/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235970884
Principal investigator 1 Deciphera Pharmaceuticals Inc. $173,880.00 02/25/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235970699
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,450.56 02/25/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235970706
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,480.00 02/19/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235970612
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,445.00 02/19/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235970616
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,643.00 02/19/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235970621
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,671.00 02/19/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235970625
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,137.00 02/19/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235970630
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,623.00 02/19/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235970633
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,087.92 02/12/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235970534
Principal investigator 1 Novartis Pharmaceuticals Corporation $330,734.19 02/10/2025 Covered Recipient Teaching Hospital
Dana-Farber Cancer Institute
Phase II trial of Ribociclib in combination with Everolimus in advanced dedifferentiated liposarcoma DDL and leiomyosarcoma LMS No dispute reported 06/30/2026 1190294142
Principal investigator 1 Deciphera Pharmaceuticals Inc. $72,450.00 02/06/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235970378
Principal investigator 1 Deciphera Pharmaceuticals Inc. $130,410.00 01/30/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235970327
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,087.92 01/30/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235970335
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,423.00 01/22/2025 Non-covered Recipient Entity
THE AMERICAN OCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235970090
Principal investigator 1 Novartis Pharmaceuticals Corporation $594,577.01 01/17/2025 Covered Recipient Teaching Hospital
American Oncologic Hospial
Phase II trial of Ribociclib in combination with Everolimus in advanced dedifferentiated liposarcoma DDL and leiomyosarcoma LMS No dispute reported 06/30/2026 1190294497
Principal investigator 1 Deciphera Pharmaceuticals Inc. $43,470.00 01/10/2025 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1235969825